Connective tissue growth factor promotes temozolomide resistance in glioblastoma through TGF-β1-dependent activation of Smad/ERK signaling

Limited benefits and clinical utility of temozolomide (TMZ) for glioblastoma (GB) are frequently compromised by the development of acquired drug resistance. Overcoming TMZ resistance and uncovering the underlying mechanisms are challenges faced during GB chemotherapy. In this study, we reported that...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeng, Huijun, Yang, Zhao, Xu, Ningbo, Liu, Boyang, Fu, Zhao, Lian, Changlin, Guo, Hongbo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5520906/
https://www.ncbi.nlm.nih.gov/pubmed/28617438
http://dx.doi.org/10.1038/cddis.2017.248

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5520906/
https://www.ncbi.nlm.nih.gov/pubmed/28617438
http://dx.doi.org/10.1038/cddis.2017.248

Ejemplares similares